These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 22986394)

  • 1. ACP Journal Club. Review: new oral anticoagulants reduced stroke and systemic embolism compared with warfarin in AF.
    Klein L
    Ann Intern Med; 2012 Sep; 157(6):JC3-2. PubMed ID: 22986394
    [No Abstract]   [Full Text] [Related]  

  • 2. ACP Journal Club. Apixaban reduced stroke or systemic embolism more than warfarin in AF regardless of renal function.
    Jones MM
    Ann Intern Med; 2012 Dec; 157(12):JC6-7. PubMed ID: 23247956
    [No Abstract]   [Full Text] [Related]  

  • 3. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation.
    Deedwania PC; Huang GW
    Am J Cardiovasc Drugs; 2011 Aug; 11(4):265-75. PubMed ID: 21740079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACP Journal Club. Apixaban reduced stroke and systemic embolism compared with aspirin in adults with AF for whom VKA therapy was unsuitable.
    Dunn A
    Ann Intern Med; 2011 Apr; 154(8):JC4-3. PubMed ID: 21502641
    [No Abstract]   [Full Text] [Related]  

  • 6. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
    ROCKET AF Study Investigators
    Am Heart J; 2010 Mar; 159(3):340-347.e1. PubMed ID: 20211293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
    Fox KA; Piccini JP; Wojdyla D; Becker RC; Halperin JL; Nessel CC; Paolini JF; Hankey GJ; Mahaffey KW; Patel MR; Singer DE; Califf RM
    Eur Heart J; 2011 Oct; 32(19):2387-94. PubMed ID: 21873708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.
    Uchiyama S; Ibayashi S; Matsumoto M; Nagao T; Nagata K; Nakagawara J; Tanahashi N; Tanaka K; Toyoda K; Yasaka M
    J Stroke Cerebrovasc Dis; 2012 Apr; 21(3):165-73. PubMed ID: 22440950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACP Journal Club: adding renal dysfunction to CHADS2 did not improve prediction of stroke or systemic embolism in AF.
    Clase CM; Zimmerman DL; A Thomson BK
    Ann Intern Med; 2013 Apr; 158(8):JC13. PubMed ID: 23588766
    [No Abstract]   [Full Text] [Related]  

  • 10. Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?
    Escobar C; Barrios V; Jimenez D
    Cardiovasc Ther; 2010 Oct; 28(5):295-301. PubMed ID: 20718760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis.
    Andersen LV; Vestergaard P; Deichgraeber P; Lindholt JS; Mortensen LS; Frost L
    Heart; 2008 Dec; 94(12):1607-13. PubMed ID: 18208828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACP Journal Club. Compared with warfarin, high-dose dabigatran might be cost-effective for preventing stroke in older patients with nonvalvular AF.
    Masoodi NA
    Ann Intern Med; 2011 Jun; 154(12):JC6-12. PubMed ID: 21690590
    [No Abstract]   [Full Text] [Related]  

  • 13. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
    Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventing stroke in atrial fibrillation: the SPORTIF programme.
    Lip GY
    Pathophysiol Haemost Thromb; 2005; 34 Suppl 1():25-30. PubMed ID: 15812201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.
    Diener HC;
    Cerebrovasc Dis; 2006; 21(4):279-93. PubMed ID: 16449807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
    Olsson SB; Rasmussen LH; Tveit A; Jensen E; Wessman P; Panfilov S; Wåhlander K
    Thromb Haemost; 2010 Mar; 103(3):604-12. PubMed ID: 20076850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis.
    Agarwal S; Hachamovitch R; Menon V
    Arch Intern Med; 2012 Apr; 172(8):623-31; discussion 631-3. PubMed ID: 22450212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dabigatran for the prevention of thromboembolic complications in the elderly: a RE-LY-able alternative to warfarin?
    Hughes PJ; Freeman MK
    Consult Pharm; 2012 Jun; 27(6):445-52. PubMed ID: 22698551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternatives to chronic warfarin therapy for the prevention of stroke in patients with atrial fibrillation.
    Lam YY; Ma TK; Yan BP
    Int J Cardiol; 2011 Jul; 150(1):4-11. PubMed ID: 21112648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.
    Destephan C; Waller AH; Patel RJ; Dhruvakumar S; Mazza V; Gerula C; Maher J; Kaluski E
    Minerva Cardioangiol; 2012 Aug; 60(4):425-31. PubMed ID: 22858920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.